Sign in

Charlotte Cornbill

@c-cornbill.bsky.social
68 followers 95 following 0 posts

PhD student in the evolution of antimicrobial resistance

PostsRepliesMedia
Reposted by Charlotte Cornbill
Alasdair Hubbard @dralhubb.bsky.social · 23/07/2026
🚨New Pre-print Really excited to see this manuscript out. While short, this was a lot of work with troubleshooting and optimisation at all stages and will, hopefully, be the start out groups major focus. Microbial evolution studies..(1/7) #MicroSky #UTISky www.biorxiv.org/content/10.6...
biorxiv.org
In vitro evolution of uropathogenic Escherichia coli to fosfomycin resistance in a 3D cultured human bladder microtissue model
In vitro studies of antimicrobial resistance (AMR) using laboratory growth media produce important, fundamental information. However, their inability to more closely replicate the in vivo environment ...
3218
Reposted by Charlotte Cornbill
Freya Harrison @friendlymicrobe.bsky.social · 10/11/2025
Low doses of tEDTA kill P. aeruginosa in models of chronic wound and CF lung #biofilm, but not in a model of endotracheal tube colonisation: preprint from a project led by @tosinorababa.bsky.social and implemented by a crack team of PhD students! #MicroSky www.biorxiv.org/content/10.1...
biorxiv.org
Low concentrations of tetrasodium EDTA cause significant killing of biofilm-associated P. aeruginosa in high validity models of chronic wound and CF lung infections but not in a model of endotracheal tube colonisation
Pseudomonas aeruginosa is a pathogen notorious for its antimicrobial resistance and is currently classified as a high-priority pathogen for which new drugs are needed. Tetrasodium EDTA (tEDTA) is one of the new antimicrobial compounds that have been shown to have good antibacterial and antibiofilm efficacy against P. aeruginosa. Due to the diversity and highly drug-tolerant nature of P. aeruginosa biofilms in different infection environments, it is important to carry out pre-clinical testing of new antibiofilm agents against this pathogen in media and models that accurately mimic diverse infection environments. In this study, we used different high validity media and biofilm models that mimic chronic wounds, endotracheal tubes, and cystic fibrosis lung infections to assess the efficacy of tEDTA against P. aeruginosa biofilms. We report that different infection environments influence the susceptibility of both planktonic and biofilm forms of P. aeruginosa to tEDTA. The highest tolerance to tEDTA was observed in the media and biofilm model that mimics the endotracheal tube environment. In conclusion, we show that although different infection environments influence the efficacy of tEDTA against P. aeruginosa biofilms, it has good potential for use as an alternative antimicrobial in treating P. aeruginosa-associated biofilm infections. ### Competing Interest Statement The authors have declared no competing interest.
1135
Reposted by Charlotte Cornbill
UK Health Security Agency @ukhsa.bsky.social · 08/04/2025
Our antibiotics are under threat. 💊 Antimicrobial resistance is already causing them to be less effective at fighting some infections. We’re on a mission to save these precious medicines and Andi Biotic is leading the way. www.youtube.com/watch?v=kTsO... #AMR #AntimicrobialResistance 🧪
youtube.com
Join Andi Biotic on his antimicrobial resistance (AMR) mission!
YouTube video by UK Health Security Agency
187
Reposted by Charlotte Cornbill
Alasdair Hubbard @dralhubb.bsky.social · 01/04/2025
And in a clash, we have @c-cornbill.bsky.social from Warwick (supervisor @friendlymicrobe.bsky.social) talking about the variability in AMR evolution in different host mimicking media in the "AMR - Mechanism and Regulation" (2/5)
154
Reposted by Charlotte Cornbill
Nature Reviews Microbiology @natrevmicro.nature.com · 28/03/2025
#weekendreading🔬📑 Programmable engineered bacteria as sustained-releasing antibody factory in situ for enhancing tumor immune checkpoint therapy @science.org in Science Advances #microsky www.science.org/doi/10.1126/...
science.org
Programmable engineered bacteria as sustained-releasing antibody factory in situ for enhancing tumor immune checkpoint therapy
The bacterial antibody factory promotes macrophage phagocytosis for improving immune checkpoint therapy.
071